Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
B-cell lymphoma
Biotech
Radiance joins ROR1 race, paying $15M for ADC to challenge Merck
Radiance is paying China’s CSPC Megalith $15 million upfront for rights to the ADC, securing itself a shot at challenging Merck for the opportunity.
Nick Paul Taylor
Feb 19, 2025 7:32am
Allogene’s lymphoma data show CAR-T could ‘leapfrog’ competition
Feb 14, 2025 10:35am
Astellas stops development of early-stage lymphoma CAR-T
Jan 9, 2025 6:49am
Innate antibody pits NK cells against lymphoma in animal models
Nov 15, 2024 2:00pm
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Apr 16, 2024 10:05am
Oncternal reports patient death in CAR-T dose-escalation study
Dec 28, 2023 10:52am
